CamAPS FX hybrid closed-loop system is beneficial during postpartum, study demonstrates

Continued use of the CamAPS FX hybrid closed-loop system benefits women with type 1 diabetes once they have given birth, research has indicated.

The AiDAPT postpartum study found that CamAPS FX hybrid closed-loop (HCL) system helped women maintain improved time in range during the first six months postpartum period compared to standard insulin therapy.

Current NICE clinical guidelines in the UK do not specifically address HCL use in the postpartum period when the demands of caring for a newborn are paramount.

In this trial, a total of 124 pregnant women with type 1 diabetes at nine UK sites were followed up for six months postpartum.

Eligible participants continued their randomly assigned treatment, either standard insulin therapy with continuous glucose monitoring (CGM) or HCL therapy with the CamAPS FX system – an advanced, adaptive HCL app that automatically adjusts insulin delivery on an insulin pump based on sensor glucose readings.

More than 50 per cent of the participants were ineligible for inclusion in the postpartum extension, and 57 participants consented to continue their treatment per original random allocation.

The mean age of the participants was 31 years, and they all had early pregnancy HbA_1c 59·4 mmol/mol (SD 10·5 [7·6 per cent SD 1·0 per cent]).

In the six months postpartum period, mean time spent within the target glucose range was higher (72 per cent) in the HCL group compared with the standard care group (54 per cent), the research has reported.

Results for time spent in the hyperglycaemic range (>10·0 mmol/L) and mean CGM glucose also favoured HCL. Findings also show that hypoglycaemia rates were low, with no between-group differences.

Candice Ward, CamDiab Training and Outreach Manager, said: “This new study emphasises the significant benefits the CamAPS FX HCL system offers women in the postpartum period.

“Managing glucose levels effectively during this time is crucial for overall health and well-being, and the findings demonstrate that the CamAPS FX HCL system provides a safe, reliable and supportive solution.”

She added: “We are delighted to see how this technology is achieving optimal glucose outcomes whilst reducing the burden of living with type 1 diabetes, giving women more time to focus on their new family.”

The full study can be accessed here.

Photo by Zach Lucero on Unsplash